Novo Nordisk establishes new research unit in biopharmaceuticals  

2005.08.16
Healthcare company Novo Nordisk has created a new research unit in biopharmaceuticals to strengthen the company's activities in the treatment of acute haemorrhage

Healthcare company Novo Nordisk has created a new research unit in biopharmaceuticals to strengthen the company's activities in the treatment of acute haemorrhage, based on its drug NovoSeven. The research unit will also exploit the full potential of Novo Nordisk's early-stage biopharmaceutical projects, and identify new drug targets. Dr. Terje Kalland, who has joined Novo Nordisk from the Swedish biotech company Biovitrum, will head the new unit.

Mads Krogsgaard Thomsen, group research director of Novo Nordisk says: "The establishment of an independent research unit in biopharmaceuticals must be seen in the light of our successful creation of a new portfolio of projects in cancer and inflammatory diseases, since we launched our new research strategy two years ago". The news is reported by Ritzau and on the Novo Nordisk website.

Novo Nordisk is a healthcare company and a world leader in diabetes care. The company has the broadest product portfolio in the industry, including advanced products in the area of insulin delivery systems. It also has a leading position in areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk is headquartered in Bagsværd, north of Copenhagen, and employs 20,250 people in 78 countries.

Link > Novo Nordisk 

Next step

Explore business cases

Please contact me

Name
Company
E-mail
Phone
How can we help you?

IDK
We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×